Bicycle Therapeutics (BCYC) Competitors $15.14 +0.02 (+0.13%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCYC vs. APLS, SRRK, BHVN, RNA, IMVT, OGN, PTCT, VRNA, RYTM, and MLTXShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Biohaven (BHVN), Avidity Biosciences (RNA), Immunovant (IMVT), Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Apellis Pharmaceuticals Scholar Rock Biohaven Avidity Biosciences Immunovant Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Bicycle Therapeutics (NASDAQ:BCYC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings. Which has more volatility & risk, BCYC or APLS? Bicycle Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Is BCYC or APLS more profitable? Apellis Pharmaceuticals has a net margin of -34.97% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-450.64% -27.35% -20.81% Apellis Pharmaceuticals -34.97%-103.11%-28.96% Do analysts recommend BCYC or APLS? Bicycle Therapeutics currently has a consensus target price of $36.00, suggesting a potential upside of 137.78%. Apellis Pharmaceuticals has a consensus target price of $49.94, suggesting a potential upside of 44.64%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Bicycle Therapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Apellis Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.70 Which has preferable valuation and earnings, BCYC or APLS? Bicycle Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$36.90M28.33-$180.66M-$3.29-4.60Apellis Pharmaceuticals$715.22M6.01-$528.63M-$2.03-17.01 Do insiders & institutionals believe in BCYC or APLS? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor BCYC or APLS? In the previous week, Bicycle Therapeutics had 14 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 23 mentions for Bicycle Therapeutics and 9 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.83 beat Bicycle Therapeutics' score of 0.17 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Apellis Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in BCYC or APLS? Apellis Pharmaceuticals received 208 more outperform votes than Bicycle Therapeutics when rated by MarketBeat users. However, 69.95% of users gave Bicycle Therapeutics an outperform vote while only 67.39% of users gave Apellis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBicycle TherapeuticsOutperform Votes13569.95% Underperform Votes5830.05% Apellis PharmaceuticalsOutperform Votes34367.39% Underperform Votes16632.61% SummaryBicycle Therapeutics beats Apellis Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05B$6.87B$5.19B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-4.6010.75128.2217.54Price / Sales28.33288.101,259.00139.66Price / CashN/A56.6541.2237.95Price / Book1.235.394.884.92Net Income-$180.66M$152.04M$119.69M$225.78M7 Day Performance-28.21%-4.33%16.64%-1.56%1 Month Performance-26.00%2.79%16.32%6.68%1 Year Performance-14.46%17.30%35.37%22.48% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.5654 of 5 stars$15.14+0.1%$36.00+137.8%-13.5%$1.05B$36.90M-4.60240Analyst ForecastInsider TradeHigh Trading VolumeAPLSApellis Pharmaceuticals4.721 of 5 stars$33.88+2.1%$49.94+47.4%-34.5%$4.21B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsSRRKScholar Rock3.9591 of 5 stars$43.81+4.4%$40.43-7.7%+130.0%$4.10B$33.19M-17.86140Positive NewsBHVNBiohaven3.8327 of 5 stars$40.21+4.5%$63.00+56.7%+0.3%$4.07B$462.51M-4.11239Analyst ForecastRNAAvidity Biosciences2.5121 of 5 stars$33.55+3.3%$63.60+89.6%+278.5%$4.00B$10.12M-11.28190Gap DownIMVTImmunovant1.4499 of 5 stars$27.09+3.1%$47.89+76.8%-34.7%$3.98BN/A-11.84120OGNOrganon & Co.4.851 of 5 stars$14.73-3.7%$21.33+44.8%+12.9%$3.79B$6.26B2.9110,000PTCTPTC Therapeutics3.9956 of 5 stars$47.52+2.5%$54.08+13.8%+65.6%$3.66B$937.82M-7.811,410Positive NewsVRNAVerona Pharma1.0815 of 5 stars$43.24+4.4%$43.83+1.4%+141.2%$3.51B$460,000.00-21.5730Positive NewsRYTMRhythm Pharmaceuticals4.1214 of 5 stars$56.68+2.6%$63.70+12.4%+20.3%$3.48B$77.43M-12.76140Positive NewsMLTXMoonLake Immunotherapeutics1.7963 of 5 stars$51.70+0.7%$79.88+54.5%-7.2%$3.30BN/A-39.802News Coverage Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Scholar Rock Competitors Biohaven Competitors Avidity Biosciences Competitors Immunovant Competitors Organon & Co. Competitors PTC Therapeutics Competitors Verona Pharma Competitors Rhythm Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCYC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts